CD40 Ligand Protects from TRAIL-Induced Apoptosis in Follicular Lymphomas through NF-κB Activation and Up-Regulation of c-FLIP and Bcl-xL1

The TNF family member TRAIL is emerging as a promising cytotoxic molecule for antitumor therapy. However, its mechanism of action and the possible modulation of its effect by the microenvironment in follicular lymphomas (FL) remain unknown. We show here that TRAIL is cytotoxic only against FL B cells and not against normal B cells, and that DR4 is the main receptor involved in the initiation of the apoptotic cascade. However, the engagement of CD40 by its ligand, mainly expressed on a specific germinal center CD4+ T cell subpopulation, counteracts TRAIL-induced apoptosis in FL B cells. CD40 induces a rapid RNA and protein up-regulation of c-FLIP and Bcl-xL. The induction of these antiapoptotic molecules as well as the inhibition of TRAIL-induced apoptosis by CD40 is partially abolished when NF-κB activity is inhibited by a selective inhibitor, BAY 117085. Thus, the antiapoptotic signaling of CD40, which interferes with TRAIL-induced apoptosis in FL B cells, involves NF-κB-mediated induction of c-FLIP and Bcl-xL which can respectively interfere with caspase 8 activation or mitochondrial-mediated apoptosis. These findings suggest that a cotreatment with TRAIL and an inhibitor of NF-κB signaling or a blocking anti-CD40 Ab could be of great interest in FL therapy.

[1]  J. Wrana,et al.  A chemical screen identifies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesis. , 2007, Cancer research.

[2]  U. Gerdemann,et al.  Up-regulation of c-FLIPS+R upon CD40 stimulation is associated with inhibition of CD95-induced apoptosis in primary precursor B-ALL. , 2007, Blood.

[3]  H. Burris,et al.  A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma , 2007 .

[4]  J. Pelkonen,et al.  The CD40-induced protection against CD95-mediated apoptosis is associated with a rapid upregulation of anti-apoptotic c-FLIP. , 2007, Molecular immunology.

[5]  K. Tarte,et al.  Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. , 2007, Blood.

[6]  Y. Kwon,et al.  Evidence for Two Modes of Development of Acquired Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance , 2007, Journal of Biological Chemistry.

[7]  L. Huc,et al.  TRAIL induces receptor-interacting protein 1-dependent and caspase-dependent necrosis-like cell death under acidic extracellular conditions. , 2007, Cancer research.

[8]  S. Conzen,et al.  Dexamethasone inhibits TRAIL-induced apoptosis of thyroid cancer cells via Bcl-xL induction. , 2006, European journal of cancer.

[9]  Marylène Lejeune,et al.  Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Tangye,et al.  BAFF, APRIL and human B cell disorders. , 2006, Seminars in immunology.

[11]  A. Plebani,et al.  ICOS Deficiency Is Associated with a Severe Reduction of CXCR5+CD4 Germinal Center Th Cells1 , 2006, The Journal of Immunology.

[12]  E. Solary,et al.  Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2 , 2006, Molecular and Cellular Biology.

[13]  G. Cohen,et al.  TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. , 2005, Cancer research.

[14]  M. Smyth,et al.  Cutting Edge: TRAIL Deficiency Accelerates Hematological Malignancies1 , 2005, The Journal of Immunology.

[15]  G. Cohen,et al.  Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1 , 2005, Cell Death and Differentiation.

[16]  J. Lederer,et al.  B cells. , 2005, Critical care medicine.

[17]  L. Staudt,et al.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.

[18]  T. Habermann,et al.  Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. , 2004, Blood.

[19]  F. Martín-Saavedra,et al.  A sustained activation of PI3K/NF-κB pathway is critical for the survival of chronic lymphocytic leukemia B cells , 2004, Leukemia.

[20]  J. Joseph,et al.  Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP , 2004, Oncogene.

[21]  M. Karin,et al.  The two NF-κB activation pathways and their role in innate and adaptive immunity , 2004 .

[22]  H. Stein,et al.  c-FLIP Mediates Resistance of Hodgkin/Reed-Sternberg Cells to Death Receptor–induced Apoptosis , 2004, The Journal of experimental medicine.

[23]  G. Packham,et al.  Differential regulation of cell survival by CD40 , 2004, Apoptosis.

[24]  M. Peter,et al.  Gadd45 beta mediates the protective effects of CD40 costimulation against Fas-induced apoptosis. , 2003, Blood.

[25]  W. May,et al.  Cleavage of Bax to p18 Bax accelerates stress-induced apoptosis, and a cathepsin-like protease may rapidly degrade p18 Bax. , 2003, Blood.

[26]  H. Harada,et al.  Overexpression of BAD potentiates sensitivity to tumor necrosis factor-related apoptosis-inducing ligand treatment in the prostatic carcinoma cell line LNCaP. , 2003, Molecular cancer research : MCR.

[27]  N. Munshi,et al.  CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. , 2003, Blood.

[28]  M. Peter,et al.  Gadd45 (cid:1) mediates the protective effects of CD40 costimulation against Fas-induced apoptosis , 2003 .

[29]  Xingming Deng,et al.  Cleavage of Bax to p 18 Bax accelerates stress-induced apoptosis , and a cathepsin-like protease may rapidly degrade p 18 Bax , 2003 .

[30]  S. Tait,et al.  TRAIL Receptor and CD95 Signal to Mitochondria via FADD, Caspase-8/10, Bid, and Bax but Differentially Regulate Events Downstream from Truncated Bid* , 2002, The Journal of Biological Chemistry.

[31]  L. Medeiros,et al.  The stromal composition of malignant lymphoid aggregates in bone marrow: variations in architecture and phenotype in different B‐cell tumours , 2002, British journal of haematology.

[32]  H. Shu,et al.  The short splice form of Casper/c‐FLIP is a major cellular inhibitor of TRAIL‐induced apoptosis , 2002, FEBS letters.

[33]  M. van Eijk,et al.  Death-receptor contribution to the germinal-center reaction. , 2001, Trends in immunology.

[34]  S. Korsmeyer,et al.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. , 2001, Molecular cell.

[35]  Peter Scheurich,et al.  NF-κB Inducers Upregulate cFLIP, a Cycloheximide-Sensitive Inhibitor of Death Receptor Signaling , 2001, Molecular and Cellular Biology.

[36]  P. Krammer,et al.  Cellular FLICE-inhibitory Protein Splice Variants Inhibit Different Steps of Caspase-8 Activation at the CD95 Death-inducing Signaling Complex* , 2001, The Journal of Biological Chemistry.

[37]  Y. Takahashi,et al.  Fas is required for clonal selection in germinal centers and the subsequent establishment of the memory B cell repertoire. , 2001, Immunity.

[38]  R. K Srivastava.  Intracellular mechanisms of TRAIL and its role in cancer therapy. , 2000, Molecular cell biology research communications : MCBRC.

[39]  J. Blenis,et al.  FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. , 2000, Immunity.

[40]  E. Newcomb,et al.  Cleavage of Bax enhances its cell death function. , 2000, Experimental cell research.

[41]  J. Tschopp,et al.  TRAIL receptor-2 signals apoptosis through FADD and caspase-8 , 2000, Nature Cell Biology.

[42]  P. Ghia,et al.  The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. , 2000, Advances in cancer research.

[43]  G. Cheng,et al.  NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[45]  A. López-Guillermo,et al.  Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. , 1999, Blood.

[46]  E. Newcomb,et al.  Caspase-dependent Activation of Calpain during Drug-induced Apoptosis* , 1999, The Journal of Biological Chemistry.

[47]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[48]  Ingo Schmitz,et al.  The Role of c-FLIP in Modulation of CD95-induced Apoptosis* , 1999, The Journal of Biological Chemistry.

[49]  K. Naresh,et al.  CD40-ligation-mediated protection from apoptosis of a Fas-sensitive Hodgkin's-disease-derived cell line , 1998, Cancer Immunology, Immunotherapy.

[50]  John Calvin Reed,et al.  Bax cleavage is mediated by calpain during drug-induced apoptosis , 1998, Oncogene.

[51]  D. Weisenburger,et al.  New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  J. Aster,et al.  Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. , 1998, Blood.

[53]  J. Gribben,et al.  Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. , 1998, Blood.

[54]  W. Hiddemann,et al.  In vitro activation of low-grade non-Hodgkin’s lymphoma by murine fibroblasts, IL-4, anti-CD40 antibodies and the soluble CD40 ligand , 1997, Leukemia.

[55]  Margot Thome,et al.  Inhibition of death receptor signals by cellular FLIP , 1997, Nature.

[56]  F. Herrmann,et al.  CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues. , 1997, Leukemia & lymphoma.

[57]  Y. Choi.  Differentiation and apoptosis of human germinal center B-lymphocytes , 1997, Immunologic research.

[58]  James Olen Armitage,et al.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.

[59]  Marty W. Mayo,et al.  TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB , 1996, Science.

[60]  David Baltimore,et al.  An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death , 1996, Science.

[61]  Seamus J. Martin,et al.  Suppression of TNF-α-Induced Apoptosis by NF-κB , 1996, Science.

[62]  Michael Karin,et al.  Dissection of TNF Receptor 1 Effector Functions: JNK Activation Is Not Linked to Apoptosis While NF-κB Activation Prevents Cell Death , 1996, Cell.

[63]  Y. S. Choi,et al.  Cellular and molecular factors that regulate the differentiation and apoptosis of germinal center B cells. Anti-Ig down-regulates Fas expression of CD40 ligand-stimulated germinal center B cells and inhibits Fas-mediated apoptosis. , 1996, Journal of immunology.

[64]  M. Kehry,et al.  CD40-mediated signaling in B cells. Balancing cell survival, growth, and death. , 1996, Journal of immunology.

[65]  T. Grogan.  Society for Hematopathology Program , 1996 .

[66]  C. Y. Wang,et al.  TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. , 1996, Science.

[67]  S. Fortune,et al.  Opposing roles of CD95 (Fas/APO-1) and CD40 in the death and rescue of human low density tonsillar B cells. , 1995, Journal of immunology.

[68]  D. Goeddel,et al.  TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40 , 1995, Science.

[69]  P. Krammer,et al.  Regulation of germinal center B cell differentiation. Role of the human APO-1/Fas (CD95) molecule. , 1995, Journal of immunology.

[70]  I. Berberich,et al.  Cross-linking CD40 on B cells rapidly activates nuclear factor-kappa B. , 1994, Journal of immunology.

[71]  R. Noelle,et al.  The role of CD40 in the regulation of humoral and cell-mediated immunity. , 1994, Immunology today.

[72]  T. Lister,et al.  Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system. , 1993, Blood.

[73]  I. Maclennan,et al.  Mechanism of antigen-driven selection in germinal centres , 1989, Nature.